Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment

Table 5 Cox survival analysis of predictors of overall accumulative survival in 316 hepatocelluar carcinom patients after radiofrequency ablation

Characteristic	Univariate			Multivariate
	HR	95%CI	P value	HR	95%CI	P value
Sex	1.149	0.709-1.862	0.572
Age	0.754	0.506-1.125	0.166
Pathology grade	2.509	1.593-3.952	< 0.001
Etiology of cirrhosis	0.862	0.720-1.031	0.105
Portal vein hypertension	2.686	1.826-3.951	< 0.001	2.743	1.462-5.149	0.002
Liver function enzyme (AST/ALT)	1.162	0.758-1.780	0.491
Child-Pugh classification	3.210	2.297-4.488	< 0.001	4.054	2.346-7.005	< 0.001
Serum AFP	1.501	1.021-2.206	0.039
CEUS pre-RFA	0.438	0.295-0.651	< 0.001
Number of tumor	2.293	1.518-3.463	< 0.001	2.693	1.399-5.185	0.003
Tumor size	1.318	0.879-1.978	0.181
Risky location	1.090	0.735-1.616	0.670
Type of RFA electrodes	0.191	0.077-0.473	< 0.001
Primary technical success	2.592	1.269-5.296	0.009
Number of RFA sessions	0.955	0.703-1.298	0.769

HCC: Hepatocelluar carcinoma; HR: Hazard ratio; AFP: Alpha–fetoprotein; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CEUS: Contrast enhanced ultrasound; RFA: Radiofrequency ablation.